
TanPrevent and the Case for Preventing Thousands of Melanomas
Learn why indoor tanning remains a preventable source of melanoma, what research suggests about why some patients experience difficulty stopping, and how a clinical pilot called TanPrevent could connect education with follow-up support to help them quit and stay quit.
Indoor tanning is an avoidable source of carcinogenic UV exposure, yet youth access to indoor tanning facilities remains problematic. On March 16, 2026, the FDA withdrew its 2015 proposed rule, which would have restricted UV-emitting sunlamp use to people aged 18 years and older and required users to acknowledge the risks before use.1 The withdrawal illustrates a persistent prevention gap: Evidence of harm does not guarantee the measures needed to reduce exposure.2
For some patients, discontinuing the tanning habit can be challenging. In a study at a college campus, 16 of 296 participants met research criteria for tanning dependence; this study assessed loss of control, unsuccessful efforts to cut down, and continued use despite harm, among other features.3 Clinicians should therefore ask their patients about tanning parlor use, previous attempts to stop, and what made those attempts difficult.
Experimental work offers a possible biological explanation for the difficulty some patients have in stopping tanning. In mice, repeated UV exposure activated a keratinocyte p53–proopiomelanocortin pathway, increased skin-derived β-endorphin, and produced opioid-mediated dependence.4 A blinded crossover study of 7 frequent tanners found increased blood flow in reward-associated brain regions after UV vs sham exposure.5 The human pilot study does not establish the mouse mechanism in people, but these findings make reinforcement a serious concern and an area for future research with potential relevance to prevention.
Continued tanning means continued exposure to carcinogens, so eliminating tanning behavior is the goal. In a randomized trial of 265 young women who screened positive for tanning addiction, more participants receiving tailored mobile messages reported quitting at treatment completion than those receiving standard risk education, but the groups did not differ significantly at 3 months.6 To inform future interventions, we need to learn what leads to sustained cessation rather than a return to use.
TanPrevent was organized to address this unmet need.
Figure. A Proposed Clinical Pathway for TanPrevent
In the clinical pilot, dermatologists and other clinicians could test a brief conversation guide covering tanning behavior, motivations, previous attempts to stop, and readiness for change, with planned follow-up. Medical students could help develop patient-facing materials and evaluate the project. Through a campus partnership, students could also produce source-checked videos and peer discussions developed with young people and clinical mentors. The materials would ideally help someone make a specific decision, such as declining a first session or seeking support after returning to tanning.
We advocate for dermatology societies to connect mentors with participating sites and to provide educational resources. Policy work through verified briefs for legislators and public health partners is vital. Coordination through the Derm Policy Network could help medical students assemble information on state age limits, consent exceptions, and facility oversight, with policy experts checking interpretations. This work could inform TanPrevent’s developing Policy Observatory.7 (Importantly, cosmetic indoor tanning must remain clearly distinguished from medically supervised phototherapy.)
Additionally, we need to investigate tanning patterns across education levels and sociodemographic backgrounds. A state-level melanoma analysis found higher age-standardized mortality in states with a lower sociodemographic index despite similar incidence.8 It did not assess indoor tanning or explain those differences. TanPrevent should evaluate who participates, who is lost to follow-up, whether cessation lasts, and whether indoor tanning is replaced by outdoor tanning.
We invite clinicians, medical students, researchers, and dermatology societies to work with TanPrevent.org so that together we can teach the public why they should avoid indoor tanning and help them sustain that choice.
How do you address tanning the issue of indoor tanning with your patients? Share your insights with your peers via Dermatology Times.
Hossein Akbarialiabad, MD, MSc, HMBA, is a physician and dermatology researcher committed to expanding access to care and translating scientific advances into meaningful public benefit. He is currently an internal medicine resident and maintains a research affiliation with the Department of Dermatology at Oregon Health & Science University.
Jane M. Grant-Kels, MD, is a professor of dermatology, pathology, and pediatrics; vice chair of the Department of Dermatology; director of the Cutaneous Oncology Center and Melanoma Program; and assistant residency program director at UConn Health.
References
1. FDA. General and plastic surgery devices: restricted sale, distribution, and use of sunlamp products; withdrawal of proposed rule. Fed Regist. 2026;91:12524-12525.
2. Akbarialiabad H, Hamzavi IH, Qureshi AA, Grant-Kels JM. Preventing cancer requires more than a list of carcinogens. Nature. 2026;654(8118):564. doi:10.1038/d41586-026-01847-4
2. Hillhouse JJ, Baker MK, Turrisi R, et al. Evaluating a measure of tanning abuse and dependence. Arch Dermatol. 2012;148(7):815-819. doi:10.1001/archdermatol.2011.2929
4. Fell GL, Robinson KC, Mao J, Woolf CJ, Fisher DE. Skin β-endorphin mediates addiction to UV light. Cell. 2014;157(7):1527-1534. doi:10.1016/j.cell.2014.04.032
5. Harrington CR, Beswick TC, Graves M, et al. Activation of the mesostriatal reward pathway with exposure to ultraviolet radiation (UVR) vs. sham UVR in frequent tanners: a pilot study. Addict Biol. 2012;17(3):680-686. doi:10.1111/j.1369-1600.2010.00312.x
6. Mays D, Alalwan MA, Long L, Atkins MB, Tercyak KP. Effects of a tailored mobile messaging intervention for indoor tanning cessation in young females: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2025;34(2):332-339. doi:10.1158/1055-9965.EPI-24-0964
7. About TanPrevent. TanPrevent. Accessed October 27, 2026.
8. Akbarialiabad H, Leachman SA, Taghrir MH, et al. Melanoma in the United States, 2010–2021: national trends and state-level patterns. Arch Dermatol Res. 2026;318:151. doi:10.1007/s00403-026-04588-6
Related to this article








